On May 5, 2015, the Federal Circuit granted Amgen a temporary reprieve in its fight with Sandoz regarding whether Sandoz may sell Zarxio®, its FDA-approved biosimilar to Amgen’s Neupogen® product, before completion of the pre-litigation procedures outlined in the Biologics Price Competition and Innovation Act (BPCIA). In Amgen Inc. v. Sandoz Inc., No. 2015-1499 (Fed. Cir. May 5, 2015), the Federal Circuit granted Amgen’s motion for a temporary injunction pending a June 3, 2015, hearing on Amgen’s motion for a preliminary injunction. The Federal Circuit’s temporary injunction is “effective immediately,” and the parties have 14 days to brief the court on the appropriate amount of the bond Amgen will need to post. For Amgen, the Federal Circuit’s decision comes just in time, as Sandoz had indicated it would launch Zarxio® on or around May 11, 2015. Amgen’s “Emergency Motion” for an injunction pending appeal, Sandoz’s opposition, and Amgen’s reply, can be found below:
Biologics Price Competition and Innovation Act (BPCIA), Food and Drug Administration (FDA), United States Court of Appeals for the Federal Circuit (CAFC)
Copyright © Finnegan, Henderson, Farabow, Garrett & Dunner, LLP. This article is for informational purposes, is not intended to constitute legal advice, and may be considered advertising under applicable state laws. This article is only the opinion of the authors and is not attributable to Finnegan, Henderson, Farabow, Garrett & Dunner, LLP, or the firm's clients.
Workshop
Life Sciences Workshop: Updates and Key Trends in Pharmaceutical and Biotechnology IP Law
May 2, 2024
Cambridge
Prosecution First Blog
Federal Circuit Follows Through on Amgen Enablement Analysis in Baxalta Inc. v. Genentech
January 5, 2024
Conference
Center for Intellectual Property x Innovation Policy Fall Conference
October 12-13, 2023
Arlington
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.